NCT01464593View on ClinicalTrials.gov

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2013

Conditions
Colon Cancer Liver Metastasis
Interventions
DRUG

Lyso-Thermosensitive Liposomal Doxorubicin

Thermally sensitive liposomal doxorubicin 50 mg/m2 single 30 minute intravenous infusion.

OTHER

5% Dextrose Solution

Single 30 minute intravenous infusion

DRUG

ThermoDox

ThermoDox is a Lyso-thermosensitive Liposomal Doxorubicin designed to be used in conjunction with thermal ablation.

Trial Locations (4)

10467

Montefiore Medical Center, The Bronx

44195

Cleveland Clinic Hospital, Cleveland

90095

UCLA, Los Angeles

02903

Rhode Island Hospital, Providence

Sponsors

Lead Sponsor

Imunon
All Listed Sponsors
lead

Imunon

INDUSTRY

NCT01464593 - Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC) | Biotech Hunter | Biotech Hunter